Author: Elena Morales

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5124

Report Highlights:

• Early detection offers promise of saving lives
• Liver transplant gives a new life to patients
• Disease recurrence within 5 years of liver transplantation boosts market growth

A World Health Organization study found that implementing vaccination, diagnostics, medication, and education could prevent 4.5 million early deaths in low- and middle-income countries by 2030. The global hepatitis strategy aims for a 90% reduction in new infections and a 65% decrease in fatalities between 2016 and 2030, supported by all WHO members.

Autoimmune hepatitis is a chronic liver disease that occurs when the body’s immune system mistakenly attacks healthy liver cells, causing inflammation and damage. It’s unclear why this happens, but genetic factors, environmental triggers, and an overactive immune response are believed to play a role.

Symptoms of autoimmune hepatitis can vary widely and include fatigue, jaundice, abdominal discomfort or pain, nausea, loss of appetite, dark urine, joint pain, and unexplained weight loss. Some people may not have any symptoms, especially in the early stages of the disease.

Early diagnosis and appropriate treatment are crucial for several reasons. AIH can progress over time and lead to severe complications such as cirrhosis (scarring of the liver), liver failure, and even liver cancer if left untreated. Early detection allows for prompt initiation of treatment, which can help slow down or stop the progression of the disease, reduce inflammation, and prevent further liver damage.

Non-Invasive Imaging Technique

• In 2023, a study in Hepatology International talked about how FibroScan and elastography are becoming more critical for diagnosing and tracking autoimmune hepatitis. Other research showed they work well compared to liver biopsy.
• In 2022, a review in Ultrasound in Medicine & Biology found that FibroScan was good at checking liver fibrosis in autoimmune hepatitis patients, even in the early stages.

Diagnosis of autoimmune hepatitis typically involves a combination of medical history review, physical examination, and blood tests to check liver function and detect specific antibodies associated with autoimmune hepatitis. Imaging studies such as ultrasound or MRI to assess liver damage, and sometimes a liver biopsy to confirm the diagnosis and determine the extent of liver inflammation and scarring.

Treatment for autoimmune hepatitis usually involves medications to suppress the immune system and reduce inflammation. These may include corticosteroids like prednisone and other immunosuppressants such as azathioprine or mycophenolate mofetil. Treatment aims to achieve remission, where liver inflammation is under control and liver function returns to normal or near-normal levels.

It’s essential for individuals with autoimmune hepatitis to follow their treatment plan carefully and regularly monitor their liver function with blood tests. They may also need ongoing medical care and regular follow-up appointments with a hepatologist (liver specialist) or gastroenterologist to ensure the disease remains under control and to address any complications or side effects of treatment.

Early diagnosis and appropriate treatment prevent complications, slow disease progression, and improve long-term outcomes. If you or someone you know experiences symptoms suggestive of liver problems, seeking medical attention promptly for evaluation and management is essential.

Increasing Prevalence of Autoimmune Hepatitis

The increasing incidence of autoimmune hepatitis worldwide is a significant driver of growth in the diagnosis and treatment market. This trend can be attributed to several factors. There has been a considerable improvement in awareness about autoimmune hepatitis among healthcare providers and the general public. This heightened awareness has led to more individuals seeking medical attention for symptoms suggestive of liver problems, leading to more diagnoses.

For instance,

• Autoimmune hepatitis affects more females than males, with a ratio of 3.6 to 1. Exact epidemiological data is lacking, so the true incidence and prevalence in the United States are unknown. However, it’s estimated that 100,000 to 200,000 individuals are affected each year. Given the increasing prevalence of liver diseases, it’s crucial to provide appropriate treatment for autoimmune hepatitis.

Advancements in medical technology have revolutionized the diagnostic process for autoimmune hepatitis. New and improved diagnostic tools and techniques have been developed, allowing for more accurate and efficient disease detection. For example, blood tests can detect specific antibodies associated with autoimmune hepatitis, while imaging techniques like MRI and ultrasound can assess liver damage more precisely.

Recent Development

• In January 2022, the Food and Drug Administration approved Lupin’s Tenofovir alafenamide tablets for treating chronic hepatitis B viral infection.
• In June 2022, Echosens and Novo Nordisk joined forces to use more accessible tests to diagnose a liver condition called NASH without invasive procedures. They aim to increase the number of NASH diagnoses by four times by 2025, especially for those with more severe cases.

Autoimmune Hepatitis Diagnosis and Treatment Market Companies

• Abbott
• Siemens Healthcare Private Limited
• Beckman Coulter
• Roche Diagnostics
• Pfizer Inc
• GE Healthcare
• Philips Healthcare
• Cadila Pharmaceuticals
• Bristol Myers Squibb Company
• Merck & Co., Inc.

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/autoimmune-hepatitis-diagnosis-and-treatment-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5124

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

The hemato-oncology testing market was valued at $3.17 billion in 2023 and is projected to grow to $9.78 billion by 2033. This growth reflects an anticipated compound annual growth rate (CAGR) of 12.4% from 2024 to 2033.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5123

Insight Highlights:

• Service offerings currently hold the leading position, accounting for a significant 58% market share in 2023.
• Leukemia, a type of blood cancer, remains the most prevalent target, capturing a 40% market share in 2023.
• PCR (polymerase chain reaction) technology reigns supreme in the testing methods, holding a commanding 45% share in 2023 due to its accuracy and efficiency.

In 2024, non-Hodgkin lymphoma (NHL) comprised about 4% of all US cancers, with an estimated 80,620 new cases and 20,140 deaths. Early diagnosis and effective treatments have decreased NHL incidence and mortality rates.

In 2024, non-Hodgkin lymphoma (NHL) is projected to account for about 4% of all cancers in the US, with an estimated 80,620 new cases and 20,140 deaths. Early diagnosis and effective treatments have decreased NHL incidence and mortality rates.

Hemtao oncology is a medical specialty that diagnoses, treats, and manages cancers and blood disorders. Hemato oncology doctors are specially trained to handle various conditions related to blood cancers (like leukemia, lymphoma, and myeloma) and other types of cancers. They use treatments such as chemotherapy, targeted therapy, immunotherapy, radiation therapy, and stem cell transplantation to help patients. This field requires a good understanding of how cancer and blood disorders work, and hemato oncology often works closely with other specialists to provide the best care possible for patients.

It’s super important to catch cancers and blood disorders early for many reasons. First, we can start treatment sooner when we find them early, which usually leads to better outcomes. Sometimes, we can even cure the cancer if we catch it early enough. When cancer is caught early, it’s less likely to spread to other parts of the body, which makes treatment more accessible and lowers the chances of bad stuff happening. Early treatment also helps people feel better faster and improves their overall quality of life. If we don’t treat blood disorders quickly, they can cause all sorts of problems like anemia or bleeding issues that mess with daily life. Another significant benefit of catching these things early is that it opens up more options for treatment. Some treatments work better in the early stages, so the sooner we see it, the more choices we have. And let’s not forget about the money side of things – treating these conditions early can save a lot of money in the long run by avoiding extensive, expensive treatments or hospital stays down the road. So yeah, catching cancers and blood disorders early is a huge deal.

When more people need treatments for cancers and blood disorders, the market for stuff related to hematology gets bigger, too. Big drug companies spend money on new drugs and medicines that work better. Other medical tool companies are also trying to create better machines to find and monitor these problems early. And because more people need help, doctors who know much about hemato oncology get busier. They’re in demand for things like talking to patients, doing tests, and giving treatments. So, as more people need help with these conditions, everyone involved in treating them gets busier, too.

More People are Getting Hemo-oncological Cases Nowadays

The rising prevalence of cancer, including Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), is mainly due to various factors like people getting older, changes in lifestyle, and exposure to certain things in the environment. As people live longer, their chances of developing cancers, including lymphomas, increase. Lifestyle factors like smoking, unhealthy diets, and lack of exercise also contribute to the risk. Environmental factors such as pollution and exposure to chemicals can play a role, too.

For Hodgkin lymphoma, while it’s not as common as some other cancers, its prevalence is still affected by these factors. It mainly affects young adults and older people.

• In 2020, according to the National Cancer Institute, approximately 223,512 people were living with Hodgkin lymphoma in the United States. Every year, about 2.5 out of every 100,000 men and women are diagnosed with Hodgkin lymphoma, and about 0.3 out of every 100,000 men and women die from it. These numbers were adjusted for age based on cases and deaths from 2016 to 2020.

Recent Developments

• In 2021, QIAGEN N.V. from Germany and Denovo Biopharma LLC from the U.S. worked together to create a blood test that helps doctors treat diffuse large B-cell lymphoma (DLBCL), a common type of cancer.
• In 2021, Illumina, Inc. from the U.S. bought GRAIL, another U.S. company. Additionally, QIAGEN worked with DeNovo to develop a blood test for treating DLBCL.
• In 2020, Thermo Fisher Scientific Inc. from the U.S. and First Genetics JCS from Russia teamed up with First Genetics to sell genetic tests in Russia.

Hemato Oncology Testing Market Companies

• F. Hoffmann-La Roche Ltd.
• Qiagen N.V.
• Abbott
• EntroGen, Inc.
• Illumina Inc.
• Thermo Fisher Scientific, Inc.
• Bio-Rad Laboratories
• Sysmex Corporation
• Danaher Corporation
• Beckman Coulter, Inc.

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/hemato-oncology-testing-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5123

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

The synovial sarcoma treatment market was valued at USD 822.74 million in 2023 and is projected to grow to USD 1,144.84 million by 2033, with an estimated CAGR of 3.6% over the forecast period. Surgery continues to be the primary treatment method, commanding a substantial 56% market share in 2023. North America leads the market, accounting for 41% of the share in the same year.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5121

According to the National Institute of Health, synovial sarcoma, a type of mesenchymal tumor commonly diagnosed in individuals under the age of 30, requires appropriate treatment for management. As the occurrence of synovial sarcoma rises, there is an increasing demand for innovative therapies to address this medical need.

Synovial sarcoma is a type of cancer that typically affects young adults and teenagers. It starts in the soft tissues, like muscles or tendons, usually around the joints in the arms or legs. Despite its name, it doesn’t develop from the synovium, which is the lining of joints. Instead, it gets its name because, under the microscope, it looks similar to cells found in the synovium. Synovial sarcoma can be aggressive and may spread to other parts of the body. It’s often treated with a combination of surgery, chemotherapy, and radiation therapy. Early detection and treatment are essential for better outcomes.

Report From National Institute of Health

• As per the National Institute of Health, the occurrence of synovial sarcoma, a type of mesenchymal tumor commonly diagnosed in individuals under the age of 30, is on the rise with each passing day. Despite being infrequent, with an annual reporting of 800 to 1000 cases, synovial sarcoma is distinctively identified by a specific chromosomal translocation involving chromosomes X and 18. This translocation event triggers the formation of SS18:SSX fusion proteins, which are integral to the pathology of this malignancy. Consequently, the medical community is increasingly attentive to this condition due to its emerging prevalence and the molecular intricacies underlying its development.

Synovial sarcoma is crucial to treat and diagnose early because early detection and treatment can significantly improve outcomes. This type of cancer can grow and spread rapidly if left unchecked, making it harder to treat as it progresses. By catching synovial sarcoma early, doctors can intervene before it spreads to other body parts, making treatment more effective and increasing the chances of successful recovery. Additionally, early diagnosis allows for less invasive treatment options, reducing the potential for complications and improving the quality of life for patients. Therefore, it’s essential to seek medical attention promptly if there are any signs or symptoms suggestive of synovial sarcoma to ensure the best possible outcome.

For instance,

• In June 2022, Advenchen Laboratories, LLC announced that they, along with Jiangsu Chia Tai Tianqing Pharmaceutical, are starting the Phase 3 clinical trial to test a potential treatment for synovial sarcoma. The therapy, called Catequentinib (previously known as anlotinib), is a pill that blocks specific proteins in the body to help fight cancer. This trial is important in testing whether this medication is safe and effective for treating synovial sarcoma.

The market for synovial sarcoma treatment is expected to increase because more cases of this type of cancer are being diagnosed. As our understanding of the disease improves, doctors can better identify and treat it. Additionally, advances in medical research and technology are leading to the development of more effective treatments. As a result, a growing demand for medications, therapies, and medical services related to synovial sarcoma drives the market’s growth.

Increasing Prevalence of Synovial Sarcoma

The American Cancer Society projects that in 2024, approximately 13,590 new cases of soft tissue sarcomas will be diagnosed in the United States. Among these cases, around 7,700 are expected to occur in males and 5,890 in females. Additionally, it is estimated that about 5,200 individuals will succumb to soft tissue sarcomas, with approximately 2,760 males and 2,440 females losing their lives to this type of cancer.

The increasing number of synovial sarcoma diagnoses creates a pressing demand for effective treatments. Imagine a scenario where a popular toy suddenly becomes highly sought after – to meet the market, and stores ramp up production.

• In 2023, around 13,400 individuals in the United States are expected to receive a diagnosis of soft-tissue sarcoma, with about 7,400 cases in males and boys and 6,000 cases in females and girls. Additionally, it is anticipated that approximately 5,140 people will pass away from this illness in the United States during the same year, with roughly 2,720 deaths in males and boys and 2,420 deaths in females and girls.

Synovial sarcoma, the growing patient population, drives the need for more treatment options. This spurs doctors and scientists into action, prompting intensified efforts to develop innovative medicines and therapies personalized to combat the cancer’s specific characteristics. With more patients seeking treatment, pharmaceutical companies and hospitals recognize the market potential and invest heavily in research and development.

For instance,

• In March 2022, C4 Therapeutics revealed that the FDA granted Orphan Drug Designation (ODD) to CFT8634 for treating Soft Tissue Sarcoma. This medication is designed to specifically target tumors dependent on BRD9, like synovial sarcoma, and tumors with SMARCB1 deletion. C4 Therapeutics focuses on developing innovative small-molecule drugs to transform disease treatment.

This influx of resources fuels advancements in understanding the disease and creating new treatment modalities. As a result, the cycle continues: more diagnoses lead to more significant investment in research, yielding more treatment options. Ultimately, this iterative process drives the growth of the synovial sarcoma treatment market, ensuring patients have improved access to the care they urgently need.

Ongoing Research and Development

Researchers are deeply invested in unraveling the complexities of synovial sarcoma, meticulously examining its intricate components to understand how the disease operates at its core. This profound understanding is the foundation for developing targeted treatments, akin to crafting a precisely fitting key to unlock a door, where these therapies are designed to attack cancer cells while sparing healthy tissue selectively.

Additionally, the advent of personalized medicine allows for the customization of treatments to suit the individual characteristics of each patient, resembling customized-made personalized clothing to fit perfectly. Concurrently, ongoing research efforts drive the development of novel drugs customized specifically to combat synovial sarcoma, broadening the spectrum of available treatment options and potentially enhancing patient outcomes and quality of life.

For instance,

• In July 2020, the European Medicines Agency (EMA) granted special status to Adaptimmune’s ADP-A2M4 for treating synovial sarcoma. This decision gives the company extra help from experts and regulators to speed up the drug’s development, possibly making it available to patients sooner.

Furthermore, specific treatments directly assail cancer cells and bolster the body’s inherent defense mechanisms against the disease, offering an additional layer of protection. Clinical trials play a pivotal role in evaluating the safety and efficacy of these emerging treatments, providing invaluable data to refine and further develop therapeutic strategies while attracting essential funding for continued research endeavors. This relentless pursuit of understanding and innovation in synovial sarcoma treatment holds immense promise for improving patient outcomes and propelling advancements in the field.

For instance,

• In January 2022, Salarius Pharmaceuticals, Inc., a company that works on developing new medicines for various cancers, including sarcomas and pediatric cancers, made an official agreement to buy a collection of potential cancer-fighting drugs from DeuteRx, LLC. Salarius renamed the leading drug candidate SP-3164 (previously known as DRX-164) and also acquired related patents. This deal also allows Salarius to find more cancer-fighting drugs in the same area of research.

Chemotherapy is Highly Recommended for the Management of Synovial Sarcoma

Chemotherapy is essential for treating synovial sarcoma, and it helps the market for these treatments in a few ways. First, it’s often the primary treatment doctors use, especially when surgery or radiation isn’t an option. So, there’s always a need for chemotherapy drugs, which keeps the market going strong.

Additionally, chemotherapy is often used alongside other treatments like surgery or radiation to lower the chances of the cancer coming back. This makes chemotherapy a crucial part of overall treatment plans. When synovial sarcoma has spread or can’t be cured, chemotherapy is used to help manage symptoms and make patients feel better. This means there’s always a demand for these drugs, even if they can’t cure the cancer.

Combining different types of treatments for cancer is showing promise in trials

• Chemotherapy + Immunotherapy: Mixing traditional chemotherapy with drugs that boost the immune system, like pembrolizumab or nivolumab, to help the body fight cancer cells.
• Chemotherapy + Target Therapies: Pair chemotherapy with drugs that target specific molecular pathways in synovial sarcoma, aiming to improve the treatment’s effectiveness and possibly overcome resistance to drugs.

Because there’s a significant demand for better chemotherapy drugs, pharmaceutical companies keep working on new ones. This helps expand the market by giving patients more options for treatment. Furthermore, ongoing research studies, called clinical trials, test out new chemotherapy treatments. If these trials show positive results, it could lead to new drugs being approved and more choices for patients.

Synovial Sarcoma Treatment Market Companies

• Novartis
• Eli Lilly and Company
• Adaptimmune
• Takara Bio Inc.
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• Eisai Co., Ltd.
• Aadi Biosciences
• Immunocore Ltd.
• GlaxoSmithKline

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/synovial-sarcoma-treatment-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5121

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

The global atrial fibrillation treatment market, valued at USD 23.06 billion in 2023, is anticipated to reach USD 37.42 billion by 2033, with a compound annual growth rate (CAGR) of 5.2% over the forecast period.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5120

Atrial Fibrillation Treatment Market Insight Highlights:

• Atrial fibrillation treatment is gaining traction! The market surged to USD 23.06 billion in 2023.
• It’s projected to hit a healthy USD 37.42 billion by 2033.
• It is estimated to register a 5.2% CAGR over the forecast period.
• Catheter ablation leads the charge, holding a dominant 54% market share in 2023 and showcasing its effectiveness in controlling irregular heartbeats.
• Catheter ablation is also set to be the fastest-growing segment, further solidifying its dominance in the AFib market.

The National Institute of Health says atrial fibrillation is on the rise globally, especially with age. They predict that by 2050, the number of people with this condition could double or triple. This highlights the urgent need for better treatment options as the prevalence increases.

Heart and blood vessel diseases, known as cardiovascular diseases (CVDs), are increasingly prevalent, causing around 17.9 million deaths globally each year. These conditions encompass heart attacks, strokes, atrial fibrillation, and others. Heart attacks and strokes make up over 80% of CVD deaths, with one-third happening before age 70.

For instance,

• In 2021, the World Heart Federation estimates that Heart diseases, also known as cardiovascular diseases (CVDs), are still the main reason why people die worldwide, causing around 20.5 million deaths in the year 2021.
• In 2021, the United States saw the highest number of heart transplants ever, with 3,817 performed. California, Texas, New York, and Florida had the most heart transplant surgeries, with California leading at 529, followed by Texas with 359, New York with 307, and Florida with 263.

Atrial fibrillation is a common problem with the heart’s rhythm. It happens when the upper chambers of the heart don’t beat regularly. Instead, they quiver or shake. This can make it hard for the heart to pump blood properly and can raise the chance of blood clots forming in the heart. A few things can cause atrial fibrillation, like having high blood pressure, heart disease, being overweight, having sleep problems like sleep apnea, or drinking too much alcohol. Doctors usually find atrial fibrillation by doing a test called an electrocardiogram (ECG), which checks for irregular heartbeats. It’s super important to catch atrial fibrillation early because it can lead to severe problems like strokes, heart failure, and other heart issues. Treating atrial fibrillation quickly with medications like blood thinners to stop clots from forming or procedures like catheter ablation to fix the heart’s rhythm can really help manage atrial fibrillation and lower the risks. The market for treating atrial fibrillation has been growing a lot because more people are becoming aware of it, technology in medicine is getting better, and there are more risk factors like getting older and changing lifestyle habits. So, scientists are constantly working on new ways to help people with atrial fibrillation have better outcomes.

Recent Developments

• In February 2023, Abbott got the green light from the European Union and the US FDA for its TactiFlex Ablation Catheter and Sensor Enabled products. These cool catheters are designed to treat abnormal heart rhythms, like atrial fibrillation. They have a bendy tip and can sense how much force they put on the heart. The FlexAbility Ablation Catheter and Sensor Enabled got extra approval from the US FDA, meaning it can now be used to treat patients with complicated heart issues.
• In November 2021, Medtronic, India, invented the Arctic Front Cardiac Cryoablation Catheter System. This tool helps treat atrial fibrillation by targeting a part of the heart and stopping abnormal electrical signals. These new technologies and treatments are expected to improve healthcare for patients with heart problems, leading to better outcomes.

Atrial Fibrillation Treatment Market Companies

• Boston Scientific Corporation
• Johnson & Johnson Med Tech
• Pfizer
• Bristol Myers Squibb
• Boehringer Ingelheim
• Bayer
• Novartis
• AtriCure, Inc.
• Medtronic
• Abbott

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/atrial-fibrillation-treatment-market-sizing 

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5120

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

The glutamine market, valued at USD 130.94 million in 2023, is projected to reach USD 175.27 million by 2033, growing at a 3.2% CAGR. L-glutamine dominates with an 83% market share, while muscle-building applications lead with 36% in 2023. North America holds the largest market share at 40%, though other regions are expected to gain traction in the fitness trend.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5119

MuscleTech Platinum 100% Glutamine is a top-notch sports nutrition product made of pure L-glutamine powder. It’s been proven in studies to help muscles recover faster and decrease soreness after working out. This product is in high demand because athletes find it useful for their training needs.

The glutamine market has witnessed significant growth owing to its diverse applications and increasing awareness of its health benefits. Glutamine, an essential amino acid found abundantly in various foods, serves as a fundamental building block for proteins. It supports immune function by aiding in the body’s defense against infections and also plays a crucial role in maintaining digestive health, particularly in the integrity of the intestinal lining. Given its importance, glutamine has become a popular dietary supplement, with healthcare professionals and consumers recognizing its significance in promoting overall well-being.

In 2022, the American Cancer Society estimated that about 1.92 million people in the United States will get cancer, and around 609,360 will pass away from it. Globally, that adds up to 9.6 million lives lost to cancer. Because diseases like cancer are becoming more common, there’s a significant need for new and better treatments all around the world. One treatment that’s getting attention is using a substance called glutamine to help manage cancer. Glutamine is a type of amino acid that seems to help people going through cancer treatment stay healthier overall. Adding glutamine to cancer treatments is part of a more significant effort to make sure patients do better and feel better during their treatment. Since diseases like cancer keep causing big problems, it’s really important for doctors and scientists to keep looking for new and better ways to treat them.

Recent Newsletter

• In September 2023, Johns Hopkins Medicine shared exciting findings from early tests of a new type of medicine called a “prodrug” that targets glutamine in tumors. This drug explicitly attacks cancer cells, starving them and making immunotherapy treatments more effective. Although it’s still being studied in labs and not ready for patients, it shows promise for improving cancer treatments.

Additionally, The rising prevalence of medical conditions such as cancer, HIV/AIDS, and digestive disorders has led to an increased demand for glutamine. Patients with these conditions often have elevated requirements for glutamine to support their treatment and manage associated symptoms. Pharmaceutical formulations and supplements containing glutamine have become essential components of their therapeutic regimens.

Furthermore, ongoing research into the therapeutic potential of glutamine continues to drive innovation in product development and treatment protocols. As scientists uncover its physiological functions and benefits, new applications and formulations are being explored, further expanding the glutamine market. The outlook for the glutamine market remains promising, with continued growth anticipated as its importance in healthcare and medical treatment becomes increasingly recognized and validated.

Recent Developments

• In September 2020, Evonik, a German firm dealing with glutamic acid, and Unilever, a British corporation making consumer goods, partnered strategically. Evonik’s biotech know-how would serve as a critical tenet for Unilever’s Clean Future program through this partnership.
• In 2020, Kyowa Kirin and Ajinomoto worked together to study fermented glutamine for sports nutrition products. They wanted to see if it could make athletes perform better.

Glutamine Market Companies

• Kyowa Hakko Kirin Co., Ltd.
• Ajinomoto Co., Inc.
• Evonik Industries AG
• Metabolic Technologies, Inc.
• Fufeng Group
• Nutritech
• Battery Nutrition Limited
• Allmax Nutrition INC.
• Nutri Advanced Ltd
• Optimum Nutrition

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/glutamine-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5119

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

The ulcerative colitis treatment market, valued at USD 10.16 billion in 2023, is projected to grow at a 4.1% CAGR, exceeding USD 14 billion by 2033. Pancolitis, which affects the entire colon, poses the greatest challenge, accounting for 34% of the market share in 2023. Anti-TNF biologics currently lead the treatment landscape, representing 30% of the medication market. While North America holds a significant 39% share, global efforts are expanding to find new solutions.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5118

National Library of Medicine estimates that ulcerative colitis impacts between 9 and 20 individuals per 100,000 annually, with an overall prevalence of 156 to 291 cases per 100,000; the management of ulcerative colitis underscores the growing need for effective treatment interventions.

Ulcerative colitis is a chronic condition where the inner lining of your large intestine and rectum gets swollen and forms sores. We’re not sure why it happens, but it might concern genes, the environment, and how your immune system works. It’s a common problem worldwide. This disease primarily affects the inner part of your large intestine, starting from the bottom and moving up. When it acts up, you might feel belly pain, have watery diarrhea (sometimes bloody), bleeding from your bottom, feel like you need diarrhea urgently, get tired, lose weight, or have a fever. You’ll occasionally feel okay for a while, and then it returns. Doctors try to help by calming down the swelling, managing your symptoms, and helping you feel better overall. They might suggest taking medicine, changing what you eat, making some lifestyle changes, or even having surgery. In the US, many people see doctors for this, which costs a ton of money yearly. It’s a problem you must deal with for a long time, and it can affect your body and emotions.

The following figure depicts the age-based distribution of IBD diagnoses. Abbreviations: CD (Crohn’s disease); IBD (inflammatory bowel disease); IBDU (IBD unclassified); UC (ulcerative colitis), according to the MDPI study.

Advances in Ulcerative Colitis: Current Treatments and the Future of Personalized Medicine

Ulcerative colitis is a chronic inflammatory disease that affects the rectum and colon. As of 2023, about 5 million people worldwide are living with this condition, and the incidence is rising. This disease typically occurs in individuals who are genetically predisposed and have been exposed to certain environmental factors. Key contributors to the development of ulcerative colitis include defects in the gut epithelial barrier, imbalances in gut microbiota, and a dysregulated immune response.

Patients with ulcerative colitis often experience bloody diarrhea. Diagnosis is made through a combination of clinical evaluation, biological tests, endoscopic examination, and histological analysis. The primary goals of medical treatment are to quickly induce a clinical response, normalize biomarkers, maintain remission, and achieve endoscopic healing to prevent long-term complications.

To induce remission, treatments typically involve 5-aminosalicylic acid drugs and corticosteroids. For maintaining remission, options include 5-aminosalicylic acid drugs, thiopurines, biologics (such as anti-cytokines and anti-integrins), and small molecule drugs (like Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators). Despite the expanding range of therapies, 10–20% of patients with ulcerative colitis still require proctocolectomy due to refractory disease. Combining these therapies with precision and personalized medicine may be key to overcoming this therapeutic challenge.

As more people are diagnosed with ulcerative colitis, it’s essential to know that medications and proper treatment can help control the condition. Along with medicine, changing what you eat can also make a big difference. Some folks feel better by avoiding certain foods like dairy, spicy dishes, and foods high in fiber. Eating smaller meals more often and drinking plenty of water can also help. In severe cases where medicine doesn’t work, surgery to remove the colon might be needed. But don’t worry. It’s usually the last option and can bring long-lasting relief for many patients. Nowadays, more effective treatments, like biological therapies, are available. As more people learn about ulcerative colitis and get diagnosed, the demand for better treatments keeps growing.

Increasing Cases of Ulcerative Colitis

As more people are diagnosed with ulcerative colitis, it’s becoming clear that this condition can have a significant impact on daily life. Dealing with symptoms like stomach pain and bleeding can be challenging, but getting the proper treatment and support can make a big difference. Doctors and researchers are working hard to understand why more people are getting ulcerative colitis and how to improve treatments. Everyone needs to know about this condition so those affected can get help and lead happier, healthier lives.

Highlights about Ulcerative Colitis:

• Family history is a significant factor in getting ulcerative colitis, suggesting genes play an essential role. About 8% to 14% of people with the condition have close relatives who also have it.
• In Northern Europe and North America, inflammatory bowel diseases like ulcerative colitis and Crohn’s disease are most common compared to other places around the world.
• Ulcerative colitis affects 9 to 20 out of every 100,000 people each year, with 156 to 291 cases per 100,000 people overall. Among adults, it’s more common than Crohn’s disease.

More and more people are getting diagnosed with ulcerative colitis, which means there’s a more significant need for treatments to help manage it. This has led to a rise in the ulcerative colitis treatment market. Pharmaceutical companies are spending more on research to create better medicines and therapies that can help with symptoms and make life easier for those with the condition. Advances in medical technology are also helping to develop treatments like biologics, which target the inflammation caused by ulcerative colitis. With more people looking for help and focusing on improving treatments, the market for ulcerative colitis treatments is increasing. This means more resources are finding new ways to help people, making it easier to get care, and spreading awareness about ulcerative colitis, which is good news for patients and their doctors.

Advancements in Biological Therapies

Advances in medical technology and understanding of ulcerative colitis have helped create better treatments. One exciting development is biological therapies, medicines made from living cells. These drugs target the inflammation in the body that causes ulcerative colitis symptoms. Unlike traditional medications that affect the whole immune system, biologics precisely pinpoint the problem areas, leading to more effective treatment with fewer side effects. They’re often used when other medications haven’t worked well enough. Biologic therapies are a big step forward in ulcerative colitis treatment, offering hope for better symptom control and improved quality of life for those with the condition.

Recent Update,

• In October 2023, the FDA approved Velsipty, a new medication developed by Pfizer, to treat severe cases of ulcerative colitis (UC) in adults. The drug was evaluated through two significant trials, ulcerative colitis 52 and ulcerative colitis 12, where participants were administered a daily 2-milligram dose of the medication. Results from these trials indicated that approximately 32 out of 100 individuals in the ulcerative colitis 52 trial and roughly 26 out of 100 individuals in the ulcerative colitis 12 trial experienced improvements in their condition.

Biologic therapies are a treatment for ulcerative colitis made from living cells. These medications target the body’s inflammation, which causes symptoms like stomach pain and bleeding. Biologics are unique because they’re more precise than traditional drugs. Instead of affecting the entire immune system, biologics zero in on the areas causing trouble, leading to better results with fewer side effects. They’re often used when other medications haven’t been effective enough. Biologic therapies are seen as a significant advancement in ulcerative colitis treatment, offering new hope for controlling symptoms and improving the quality of life for people with the condition.

Ulcerative Colitis Treatment Market Companies

• AbbVie
• Takeda Pharmaceuticals
• Johnson & Johnson Services, Inc.
• Pfizer
• Bristol Myers Squibb
• Merck & Co.
• Ferring Pharmaceuticals
• Sanofi
• Novartis
• Bausch Health

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/ulcerative-colitis-treatment-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5118

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Thermostable vaccines could capture at least 20% of the global vaccine market over the next decade. In 2021, the WHO reported 94 vaccine distributors worldwide, with China and India leading, hosting 23 and 7 manufacturers respectively. Together, they accounted for 32% of Western Pacific-based manufacturers, with the region housing 41% of all vaccine producers globally.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5117 

The World Health Organization estimates that immunization prevents 3.5-5 million deaths annually from diseases such as diphtheria, tetanus, pertussis, influenza, and measles, but cold storage issues damage vaccines. Thermostable vaccines can be stored at room temperature for extended periods, eliminating the need for cold chain logistics. This reduces storage and transportation costs, making mass immunization projects more affordable.

A thermostable vaccine is a type of vaccine that can maintain its effectiveness even when exposed to fluctuations in temperature. Unlike traditional vaccines that require strict refrigeration to preserve their potency, thermostable vaccines can remain viable even if not cold. This is particularly advantageous in regions with limited access to reliable refrigeration facilities, such as remote areas or during emergencies.

The importance of thermostable vaccines lies in their ability to overcome logistical challenges associated with vaccine storage and transportation. Maintaining a cold chain for vaccine distribution can be difficult in many parts of the world, especially in developing countries or areas with limited infrastructure. Thermostable vaccines solve this problem by eliminating the need for continuous refrigeration, thus expanding access to immunization programs and ensuring that more people, especially those in underserved communities, can receive vital vaccinations.

Tuberculosis (TB) spreads when sick people breathe the bacteria into the air. In 2021, TB caused 1.6 million deaths and affected 10.6 million people. The World Health Organization says almost two billion people worldwide have TB bacteria inside them. Thermostable vaccines can help manage TB.

Recent Update

• In March 2023, the Access to Advanced Health Institute (AAHI) released findings from a Phase I clinical trial showcasing the safety and effectiveness of a novel thermostable vaccine for tuberculosis (TB), the second leading cause of global infectious disease-related deaths. This TB vaccine contains various proteins from the Mycobacterium tuberculosis bacterium fused into a single protein (ID93), coupled with a specialized immune-boosting adjuvant (GLA-SE). The vaccine is presented in a freeze-dried form that doesn’t need refrigeration.

Recent Developments

• In June 2023, the Department of Biotechnology (DBT) obtained emergency approval for GEMCOVAC-OM, a thermostable booster vaccine based on mRNA technology explicitly targeting the omicron variant. This vaccine integrates indigenous platform technology.
• In April 2023, AstriVax was awarded a EUR 2.5 million grant from the Flanders Innovation & Entrepreneurship (VLAIO) agency to improve its thermostable vaccine platform.

Thermostable Vaccine Market Companies

• Serum Institute of India
• Sanofi
• GSK
• Hilleman Laboratories
• Soligenix

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/thermostable-vaccine-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5117

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

The corticosteroids market reached USD 4.71 billion in 2023 and is projected to grow to USD 6.91 billion by 2033, with a compound annual growth rate (CAGR) of 4.2% during this period. Rheumatology applications led the market in 2023, accounting for 35% of the share, while dermatology is anticipated to be the fastest-growing segment, with a 5.1% CAGR driven by demand for healthier skin. Topical corticosteroids dominated the market, holding a 49% share in 2023.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5111

The Forum of International Respiratory Societies estimates that over 4.5 million people have lost their lives due to the current pandemic, primarily from respiratory issues. Corticosteroids have been widely employed in treating respiratory diseases during this crisis.

Corticosteroids are a class of steroid hormones produced by the adrenal cortex, the outer portion of the adrenal glands located on top of each kidney. These hormones regulate various physiological processes, including metabolism, immune response, and electrolyte balance. There are two main types of corticosteroids: glucocorticoids and mineralocorticoids. Glucocorticoids, such as cortisol, regulate metabolism and the immune system, while mineralocorticoids, such as aldosterone, play a role in maintaining electrolyte and water balance.

In medicine, synthetic corticosteroids are commonly used for their anti-inflammatory and immunosuppressive properties. These medications are referred to as corticosteroid drugs or simply steroids. They can be administered in various forms, including oral tablets, topical creams or ointments, inhaled preparations, and injections. Corticosteroids are prescribed to treat a wide range of medical conditions, including autoimmune disorders, allergies, asthma, inflammatory joint diseases, and certain skin conditions.

It’s important to note that healthcare professionals should carefully monitor the use of corticosteroids due to potential side effects and the need for appropriate dosage adjustments. Prolonged or inappropriate use of corticosteroids can lead to adverse effects such as bone loss, immune system suppression, and metabolic disturbances. Therefore, these medications are typically prescribed based on a thorough assessment of the patient’s condition and careful consideration of the potential risks and benefits.

The increasing incidence of respiratory conditions, such as asthma and chronic obstructive pulmonary disease (COPD), has led to a higher demand for inhaled corticosteroids as part of the treatment regimen for these conditions. Corticosteroids continue to be a component of cancer treatment protocols, helping to manage side effects associated with chemotherapy. As cancer research advances and new treatment modalities emerge, the demand for supportive medications like corticosteroids may increase.

Impact of Covid-19

The pharmaceutical industry, along with various others, has been significantly impacted by the COVID-19 pandemic. Despite corticosteroids not being antiviral drugs, they have emerged as crucial components in the treatment of severe COVID-19 cases, particularly in individuals experiencing serious lung complications. The heightened demand for corticosteroids during the pandemic can be attributed to several key factors. One pivotal role of corticosteroids is managing cytokine storms, which are intense immune responses triggered in severe COVID-19 cases. By modulating the immune system, corticosteroids help control these storms, reducing inflammation and safeguarding vital organs.

Additionally, the pandemic has seen an increase in cases of Acute Respiratory Distress Syndrome (ARDS) induced by COVID-19, characterized by severe lung inflammation. Corticosteroids alleviate this inflammation and enhance respiratory function in critically ill patients. Evidence from various clinical trials, including the influential RECOVERY trial, has supported using corticosteroids in severe COVID-19 cases. Notably, medications like dexamethasone have demonstrated effectiveness in reducing mortality rates, particularly in patients requiring respiratory support.

For instance,

• On 30 March 2023, the World Health Organization published an R&D Blueprint about the COVID-19 landscape of Novel Coronavirus Candidates Vaccine Development worldwide.

Major health organizations, including the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), have responded to emerging evidence by updating their guidelines. These updates now recommend corticosteroids for specific severe cases of COVID-19, further contributing to the increased demand.

Many countries granted emergency approvals for using corticosteroids to address the urgency of treating severe COVID-19 cases. This facilitated quicker access to these medications for healthcare providers on the front lines of patient care. The surge in COVID-19 cases and subsequent hospitalizations during various waves of the pandemic heightened the demand for medications, including corticosteroids. Hospitals and healthcare systems proactively stocked up on these drugs to meet the needs of critically ill patients requiring intensive care.

The pandemic’s challenges have led to a boost in research efforts to understand the immune response to the virus better and identify effective treatment strategies. Corticosteroids have been explored in these research endeavors, being considered a valuable component in the evolving treatment plans against COVID-19.

Corticosteroids are Frequently Utilized in Managing Respiratory Ailments

Pulmonology’s application of corticosteroids, involving inhaling these medications directly into the lungs, is widely employed in managing respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD). This approach holds significant potential to drive the growth of the corticosteroid market for several compelling reasons.

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/corticosteroids-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5111

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

In 2023, the home healthcare market surged to USD 192.4 billion and is projected to reach USD 427.69 billion by 2033, with a strong 8.6% annual growth rate. Diagnostics and monitoring devices led the market, capturing a 59% share, while diabetes accounted for 32% of the total market. North America dominated the industry, holding a significant 44% market share.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5110

According to the International Diabetes Federation, around 536 million adults had diabetes in 2021, and this number is predicted to reach 783 million by 2045. Home healthcare services help individuals with diabetes manage their health at home, lowering the necessity for hospital visits and reducing overall care expenses.

Home healthcare is a service where healthcare professionals, like nurses and therapists, bring medical assistance and support directly to your home. This includes various services such as nursing care, physical therapy, and help with everyday activities like bathing or getting dressed. The critical concept is offering medical care for people who need it but would rather stay home than go to a hospital or clinic. This type of care is beneficial for different situations. It could be for people recovering from an illness, managing long-term health conditions, or individuals needing extra help. Home healthcare allows individuals to receive necessary medical attention while staying in a familiar and comfortable environment.

The home healthcare market has been growing for a few reasons. As the population ages, there is an increased demand for healthcare services. Older adults often prefer to age in place, and home healthcare supports that choice. Second, technological advancements and medical practices make it feasible to deliver complex healthcare services in a home setting. This includes using telemedicine for remote consultations and monitoring devices to keep track of health metrics. Additionally, the COVID-19 pandemic has accelerated the adoption of home healthcare. The desire to minimize exposure to crowded places has led more people to opt for home-based care. This has increased the demand for home healthcare services and prompted advancements in technology to make remote healthcare delivery more effective.

According to the CDC, about 12.1% of adults in the U.S. face difficulty walking or climbing stairs due to mobility-related disabilities. These disorders, affecting movement due to physical, psychological, or neurological issues, may be treated with physical therapy, assistive tools, and medications. Home healthcare services offer valuable support to individuals with mobility challenges, aiding with daily tasks to maintain independence. Physiotherapists in home healthcare help people regain mobility, functionality, and strength while reducing pain through exercises, movements, and massages. The increasing prevalence of mobility disorders drives the expected growth of this segment.

Home healthcare is a convenient and personalized way to receive necessary medical care in the comfort of one’s home. The growing aging population, technological advancements, and the changing landscape of healthcare delivery have contributed to the increasing popularity and expansion of the home healthcare market.8

Home Healthcare Market Companies

• GE HealthCare
• Amedisys
• LHC Group
• BAYADA Home Health Care
• Koninklijke Philips N.V.
• ResMed
• Becton, Dickinson And Company
• Medline Industries, Inc.
• Arkray, Inc.
• McKesson Medical-Surgical Inc.

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/home-healthcare-market-size

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5110

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5109

Healthcare providers are getting more interested and excited about mobile health (mHealth) apps, with over a third of doctors suggesting them to patients. When doctors suggest these apps, people tend to keep using them for about 30 days more than usual, with a 10% higher retention rate for health apps and 30% higher for fitness apps.

mHealth revolutionizes healthcare by utilizing mobile devices and health-related apps to enhance service delivery, monitoring, and management. The significance of mHealth in society becomes evident through its multifaceted benefits. First and foremost, it addresses the issue of accessibility, allowing individuals, particularly those in remote areas, to access health information and services regardless of geographical constraints. Additionally, mobile apps empower users to actively monitor their health, from tracking fitness levels to managing chronic conditions and receiving timely medication reminders. The advent of telemedicine through mHealth facilitates remote consultations with healthcare professionals, proving invaluable for routine check-ups.

A recent Newsletter from the World Health Organization

• On April 15, 2020, the World Health Organization (WHO) introduced a chatbot on Facebook Messenger to counteract misinformation about COVID-19. Over 12 million individuals have already accessed the WHO Health Alert service through WhatsApp. In regions severely impacted by COVID-19, the overall messaging activity on Facebook’s suite of apps had surged by over 50%. With the extension to Facebook Messenger and other associated communication channels, the WHO Health Alert had the potential to reach 4.2 billion people, aiding them in safeguarding against COVID-19, curbing its transmission, and gaining accurate insights into the disease.

Beyond individual empowerment, mHealth serves as a powerful tool for health education. Mobile apps serve as platforms for disseminating information, promoting awareness, and educating communities about healthy lifestyle choices. This proactive approach aids in disease prevention and contributes to overall community well-being. Additionally, mHealth plays a pivotal role in data collection and analytics, aggregating health data from various sources. This data-driven approach provides valuable insights for healthcare providers and policymakers, enabling the identification of health trends and formulating effective public health strategies.

The escalating global demand for mHealth can be attributed to several factors. The widespread adoption of smartphones globally expands the potential user base for mHealth applications, fostering increased demand. The COVID-19 pandemic underscored the importance of remote healthcare solutions, positioning mHealth as a critical tool for maintaining healthcare services while minimizing physical contact. The inherent convenience and efficiency of mHealth, reducing the necessity for physical visits to healthcare facilities, appeal to consumers and healthcare providers. With a rising prevalence of chronic diseases worldwide, mHealth emerges as a solution for continuously monitoring and managing these conditions, further fueling demand. Furthermore, government initiatives promoting digital health play a pivotal role in encouraging the development and widespread adoption of mHealth solutions, solidifying its position as a transformative force in global healthcare. In essence, mHealth simplifies healthcare management through smartphones, gaining international recognition for its convenience, health monitoring capabilities, and facilitation of remote healthcare services.

Adoption of Mobile Use

The surge in smartphone adoption stands as a cornerstone in propelling the expansion of the mHealth market. This phenomenon is marked by the widespread ownership and utilization of smartphones globally. The significance of this trend is underpinned by various factors that underscore the transformative impact of increased smartphone adoption in the realm of mHealth.

For Instance,

• In January 2022, AT&T partnered with Smart Meter to create advanced digital health solutions. They’re working together to use Smart Meter’s IoT devices and AT&T’s strong IoT network to monitor and track chronic conditions like diabetes.

Additionally, smartphones have evolved into ubiquitous devices, transcending diverse demographics and geographical locations. The ubiquity of smartphones ensures that a substantial portion of the global population possesses these devices, establishing a broad and varied user base for mHealth applications.

mHealth Market Companies

• Apple
• Google
• Samsung
• Philips
• Medtronic
• Teladoc Health, Inc.
• Abbott Laboratories
• Dexcom, Inc.
• Withings
• Omada Health Inc.
• Canary Health
• Welldoc, Inc.

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/mhealth-market-size

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5109

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare